AI biotech Enveda raised a $311 million Series E at a $2 billion valuation, led by Catalio Capital Management with participation from Iconiq and others. TechCrunch says the valuation doubled in a year and that the company is testing several drug candidates in patients, including candidates for severe skin conditions and maintaining weight loss after stopping GLP-1 drugs.

Editor's note

This summary is based on the primary source. Open the original for full context, data, and qualifying details.